Skip to main content
SpringerLink
Log in

Durvalumab nach einer Radiochemotherapie ist beim NSCLC im Stadium III derzeit die vielversprechendste Therapie

Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Yoon SM, Shaikh T, Hallman M (2017) Therapeutic management options for stage IIInon-small cell lung cancer. World J Clin Oncol 8:1–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergisticallypromote antitumor immunity in mice. J Clin Invest 124:687–695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy instage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Article  CAS  PubMed  Google Scholar 

  4. Antonia SJ, Villegas A, Daniel D et al (2018) PACIFIC investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

    Article  CAS  PubMed  Google Scholar 

  5. Bradley JD, Paulus R, Komaki R et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consoli-dation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Butts C, Socinski MA, Mitchell PL et al (2014) Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:59–68

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin 5, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland

    Martin Wilhelm

Authors
  1. Martin Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Wilhelm.

Ethics declarations

Interessenkonflikt

M. Wilhelm gibt an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Antonia SJ, Villegas A, Daniel D, et al.; PACIFIC Investigators (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–50

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilhelm, M. Durvalumab nach einer Radiochemotherapie ist beim NSCLC im Stadium III derzeit die vielversprechendste Therapie. Strahlenther Onkol 195, 691–692 (2019). https://doi.org/10.1007/s00066-019-01456-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01456-3

Search

Navigation